Neil Beeharry

1.4k total citations
46 papers, 1.0k citations indexed

About

Neil Beeharry is a scholar working on Molecular Biology, Surgery and Oncology. According to data from OpenAlex, Neil Beeharry has authored 46 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 17 papers in Surgery and 8 papers in Oncology. Recurrent topics in Neil Beeharry's work include Bladder and Urothelial Cancer Treatments (14 papers), DNA Repair Mechanisms (11 papers) and Urinary and Genital Oncology Studies (7 papers). Neil Beeharry is often cited by papers focused on Bladder and Urothelial Cancer Treatments (14 papers), DNA Repair Mechanisms (11 papers) and Urinary and Genital Oncology Studies (7 papers). Neil Beeharry collaborates with scholars based in United States, United Kingdom and Spain. Neil Beeharry's co-authors include Tim J. Yen, Julie A. Chambers, Irene C. Green, Marylens Hernandez, Henri S. Lichenstein, Sean F. Landrette, Paul Beckett, Jonathan M. Rothberg, Tian Xu and Shawn M. Ferguson and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Neil Beeharry

44 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Neil Beeharry United States	19	631	196	190	149	111	46	1.0k
Marie‐Josée Boucher Canada	16	657 1.0×	153 0.8×	259 1.4×	165 1.1×	131 1.2×	22	1.0k
Astrid Fauster Austria	8	764 1.2×	190 1.0×	104 0.5×	59 0.4×	159 1.4×	9	1.1k
Gen Fujii Japan	19	718 1.1×	102 0.5×	322 1.7×	116 0.8×	58 0.5×	52	1.1k
Donghui Zhou China	17	909 1.4×	450 2.3×	157 0.8×	79 0.5×	171 1.5×	53	1.4k
Xiaohua Huang Germany	18	649 1.0×	167 0.9×	180 0.9×	68 0.5×	127 1.1×	33	953
Vivian Fu United States	17	857 1.4×	219 1.1×	187 1.0×	51 0.3×	101 0.9×	20	1.2k
Jun-Ichi Sakamaki Japan	15	747 1.2×	103 0.5×	127 0.7×	140 0.9×	281 2.5×	25	1.1k
Jeong‐Min Kim South Korea	25	850 1.3×	98 0.5×	219 1.2×	84 0.6×	104 0.9×	51	1.4k
Tymon Rubel Poland	18	836 1.3×	98 0.5×	232 1.2×	109 0.7×	57 0.5×	35	1.2k

Countries citing papers authored by Neil Beeharry

Since Specialization

Citations

This map shows the geographic impact of Neil Beeharry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Neil Beeharry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Neil Beeharry more than expected).

Fields of papers citing papers by Neil Beeharry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Neil Beeharry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Neil Beeharry. The network helps show where Neil Beeharry may publish in the future.

Co-authorship network of co-authors of Neil Beeharry

This figure shows the co-authorship network connecting the top 25 collaborators of Neil Beeharry. A scholar is included among the top collaborators of Neil Beeharry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Neil Beeharry. Neil Beeharry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Roger, Gautam Jayram, Angela Girvin, et al.. (2025). MOONRISE-1: PHASE 3 STUDY OF TAR-210, AN ERDAFITINIB INTRAVESICAL TARGETED RELEASING SYSTEM, VERSUS INTRAVESICAL CHEMOTHERAPY IN PATIENTS WITH FGFR-ALTERED INTERMEDIATE-RISK NON–MUSCLE-INVASIVE BLADDER CANCER. Urologic Oncology Seminars and Original Investigations. 43(3). 53–53.

Siefker‐Radtke, Arlene O., Yohann Loriot, Nobuaki Matsubara, et al.. (2024). FGFR3 alterations (FGFRalt) in patients (pts) who develop locally advanced or metastatic urothelial cancer (mUC), and their association with tumor subtype and clinical outcomes in pts treated with erdafitinib (erda) vs. pembrolizumab (pembro).. Journal of Clinical Oncology. 42(16_suppl). 4578–4578.

Vilaseca, Antoni, Gautam Jayram, Carles X. Raventós, et al.. (2023). LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt). Annals of Oncology. 34. S1343–S1343. 16 indexed citations

Heijden, Michiel S. van der, et al.. (2021). SunRISe-1: phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk non-muscle-invasive bladder cancer unresponsive to bacillus Calmette–Guérin who are ineligible for or decline radical cystectomy. European Urology Open Science. 33. S389–S390. 2 indexed citations

Heijden, Michiel S. van der, Milin Acharya, Neil Beeharry, et al.. (2021). 719TiP SunRISe-1: Phase IIb study of TAR-200 in combination with cetrelimab (CET), TAR-200 alone, or CET alone in participants with high risk non-muscle invasive bladder cancer unresponsive to intravesical bacillus Calmette-Guérin who are ineligible for or elected not to undergo radical cystectomy. Annals of Oncology. 32. S723–S724. 2 indexed citations

Rorà, Andrea Ghelli Luserna di, Anna Ferrari, Carolina Terragna, et al.. (2019). Synergism Through WEE1 and CHK1 Inhibition in Acute Lymphoblastic Leukemia. Cancers. 11(11). 1654–1654. 22 indexed citations

Ursu, Oana, Sara J.C. Gosline, Neil Beeharry, et al.. (2017). Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens. PLoS ONE. 12(10). e0185650–e0185650. 2 indexed citations

Beeharry, Neil, Andrea Ghelli Luserna di Rorà, Mitchell R. Smith, & Tim J. Yen. (2015). Pixantrone induces cell death through mitotic perturbations and subsequent aberrant cell divisions. Cancer Biology & Therapy. 16(9). 1397–1406. 21 indexed citations

Lal, Shruti, Richard A. Burkhart, Neil Beeharry, et al.. (2014). HuR Posttranscriptionally Regulates WEE1: Implications for the DNA Damage Response in Pancreatic Cancer Cells. Cancer Research. 74(4). 1128–1140. 83 indexed citations

10.

Balaburski, Gregor M., Julia I-Ju Leu, Neil Beeharry, et al.. (2013). A Modified HSP70 Inhibitor Shows Broad Activity as an Anticancer Agent. Molecular Cancer Research. 11(3). 219–229. 80 indexed citations

11.

Bagnyukova, Tetyana, Diana Restifo, Neil Beeharry, et al.. (2013). DUSP6 regulates drug sensitivity by modulating DNA damage response. British Journal of Cancer. 109(4). 1063–1071. 29 indexed citations

12.

Budina-Kolomets, Anna, et al.. (2013). Comparison of the activity of three different HSP70 inhibitors on apoptosis, cell cycle arrest, autophagy inhibition, and HSP90 inhibition. Cancer Biology & Therapy. 15(2). 194–199. 40 indexed citations

13.

Beeharry, Neil, J. B. Rattner, Juliane P. Caviston, & Tim J. Yen. (2013). Centromere fragmentation is a common mitotic defect of S and G₂checkpoint override. Cell Cycle. 12(10). 1588–1597. 20 indexed citations

14.

Martz, Matthew, Elda Grabocka, Neil Beeharry, Tim J. Yen, & Philip Wedegaertner. (2013). Leukemia-associated RhoGEF (LARG) is a novel RhoGEF in cytokinesis and required for the proper completion of abscission. Molecular Biology of the Cell. 24(18). 2785–2794. 21 indexed citations

15.

Tu, Zhigang, Katherine M. Aird, Benjamin G. Bitler, et al.. (2011). Oncogenic Ras Regulates BRIP1 Expression to Induce Dissociation of BRCA1 from Chromatin, Inhibit DNA Repair, and Promote Senescence. Developmental Cell. 21(6). 1077–1091. 74 indexed citations

16.

Ratushny, Vladimir, Harsh B. Pathak, Neil Beeharry, et al.. (2011). Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death. Oncogene. 31(10). 1217–1227. 27 indexed citations

17.

Johnson, Jay E., Neil Beeharry, Maria Chiourea, et al.. (2010). Doxorubicin Resistance in a Novel In vitro Model of Human Pleomorphic Liposarcoma Associated with Alternative Lengthening of Telomeres. Molecular Cancer Therapeutics. 9(3). 682–692. 8 indexed citations

18.

Huang, Haomin, Neil Beeharry, René Daniel, et al.. (2008). Abnormal Cytokinesis after X-Irradiation in Tumor Cells that Override the G2 DNA Damage Checkpoint. Cancer Research. 68(10). 3724–3732. 38 indexed citations

19.

Beeharry, Neil, et al.. (2004). Analysis of cytokine-induced NO-dependent apoptosis using RNA interference or inhibition by 1400W. Nitric Oxide. 10(2). 112–118. 11 indexed citations

20.

Beeharry, Neil, et al.. (2004). Fatty acid protection from palmitic acid-induced apoptosis is lost following PI3-kinase inhibition. APOPTOSIS. 9(5). 599–607. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact